Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer
Journal article published in 2017 by
E. E. W. Cohen,
L. F. Licitra 
,
B. Burtness,
J. Fayette,
T. Gauler,
P. M. Clement,
J. J. Grau,
J. M. del Campo,
A. Mailliez,
R. I. Haddad,
J. B. Vermorken,
M. Tahara,
J. Guigay,
L. Geoffrois,
M. C. Merlano
and other authors.
,
B. Burtness,
J. Fayette,
T. Gauler,
P. M. Clement,
J. J. Grau,
J. M. del Campo,
A. Mailliez,
R. I. Haddad,
J. B. Vermorken,
M. Tahara,
J. Guigay,
L. Geoffrois,
M. C. Merlano
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 